Irreproducible research is costing the biopharma industry billions. A landmark 2015 study estimated that $28 billion is lost each year in preclinical studies in the United States.1 With R&D spending only growing, a more recent analysis suggests losses may exceed $40 billion annually in the US and almost $90 billion worldwide.2
These numbers aren’t abstract; they reflect daily challenges in biopharma labs. A Nature survey of more than 1,500 scientists confirmed that most have struggled to reproduce peers’ experiments, with direct consequences for time, cost, and credibility.3
For biopharma R&D scientists working to improve real lives, reproducibility isn't just a scientific ideal or a box-ticking exercise. It’s the foundation of productivity, efficiency, and trust in scientific results.